Our Mission

We are dedicated to establishing a drug discovery and early-stage development company that is based on innovation, scientific rigor and integrity. Our goal is to create novel products to meet critical patient needs, including: Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and Novel therapies to improve the treatment of human neurological conditions.

 
 

Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.

 

Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.

Tauopathies are neurodegenerative disorders caused by aggregation of Tau proteins with formations of neurofibrillary tangles. 
Tau aggregates are not only found in AD, but also non-AD neurodegenerative diseases, including FTD, PSP, and CBS.

Synucleinopathies are neurodegenerative disorders caused by abnormal aggregation of alpha-synuclein proteins with formations of insoluble fibrils.  

Alpha-synuclein aggregates are found in major families of synucleinopathies, which include  Parkinson Disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). 
 

 
 
 
 

News

November 20, 2019

Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer’s Disease

APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of 18F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer's Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns in healthy older adults.

August 29, 2019

APRINOIA Therapeutics has Initiated a Collaboration with Keio University in Tokyo, Japan

APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute to the study which might be useful for deeper understanding of dementia, especially Alzheimer’s Disease.

June 30, 2019

APRINOIA Therapeutics Joined JLABS @ Shanghai

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been selected to join Johnson & Johnson Innovation’s JLABS and is now a resident company of JLABS @ Shanghai.

 

For more information, please click on “More” for the original press release from Johnson & Johnson Innovation.

May 22, 2019

APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research

APRINOIA Therapeutics announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.

March 25, 2019

2019 Taiwan Top 10 Coolest Tech Startups

APRINOIA was awarded as one of the top ten most innovative startups of Taiwan in 2019 by the Ministry of Science & Technology.

December 27, 2018

2019 Human Amyloid Imaging Conference

APRINOIA will be presenting the latest clinical trial results for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami, USA in January 2019. We will deliver a total of 10 presentations with our partners.

December 24, 2018

APRINOIA Licenses Tau PET Imaging Tracer APN-1607 to Celgene

APRINOIA Therapeutics announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [18F]-labeled positron emission tomography (PET) imaging tracer, to support patient selection and efficacy evaluation in its global clinical trials.

October 11, 2018

Emerging Company Profile - APRINOIA TACKLES TAU

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.

August 31, 2018

Asia-China: 2018 Clinical Trials on Alzheimer's Disease Conference

APRINOIA will be sponsoring the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.

December 14, 2017

APRINOIA Closes US$11.1 Million Series B Financing

APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.

December 14, 2017

APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation

APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.

December 14, 2017

2018 AAT-AD/PD Focus Meeting

APRINOIA will be presenting the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.

December 14, 2017

2018 Human Amyloid Imaging Conference

APRINOIA will be presenting the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.

July 16, 2017

2017 Alzheimer's Association International Conference

APRINOIA presented "Development of novel 3rd generation PBB3 tau PET tracer (APN-1701) and resulting collection of diverse structures with unique protein aggregate binding profiles" in July 2017.

December 11, 2016

2017 International Conference on Alzheimer's Disease and Parkinson's Disease

APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the 13th International Conference on Alzheimer's Disease and Parkinson's Disease (AD&PD) in Vienna in March 2017.

December 11, 2016

2017 Human Amyloid Imaging Conference

APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2017.

December 04, 2016

2016 Taiwan Neuroscience Conference

APRINOIA is proud to host 2016 Taiwan Neuroscience Conference with Development Center for Biotechnology (DCB) and Academia Sinica on the 5th December 2016.

November 19, 2016

US FDA IND

APRINOIA has received written approval from the US FDA to conduct the first-in-the-human clinical trial in the US.

Please reload

 
 

Careers

This information will be updated shortly.
 

Contact Us

台灣

Email        : contact@aprinoia.com 

地址          : 11503 臺北市南港區園區街3號17樓 

辦公室電話: +886-2-2655-8868

Taiwan
 
Address     : 17F, No.3, Park St., Nangang District, Taipei City 11503

Phone        : +886-2-2655-8868

-------------------------------------------------------------------------------------------------------​

中国大陆

邮箱          : contact@aprinoia.com 
地址       
  : 苏州市工业园区星湖街218号 生物医药产业园B2号楼5楼503室 215123

办公室电话: +86-512-8777 8382

China

Address    : R503,5F,Building B2,218 Xing Hu Rd,Suzhou Industrial Park,Suzhou 215213

Phone       : +86-512-8777 8382

-------------------------------------------------------------------------------------------------------​

日本

Email        : contact@aprinoia.com

所在地       : 〒104ー0033 東京都中央区新川1-2-8 第5山京ビル5F

Tel              +81-3-6280-4277

Japan

Address    : Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan

Phone         +81-3-6280-4277